Zotiraciclib is an orally active inhibitor targeting JAK2, FLT3, and CDK2, with IC50 values of 13 nM, 73 nM, and 56 nM, respectively. It inhibits cancer cell proliferation, tumor growth, and the activity of CYP2D6. This compound is used in research related to colon cancer, B-cell lymphoma, advanced leukemia, acute leukemia, and multiple myeloma.
- Potent inhibitor of JAK2, FLT3, and CDK2.
- Inhibits cancer cell proliferation and tumor growth.
- Demonstrates high plasma protein binding and Caco-2 permeability.
- Exhibits metabolic stability in human and canine liver microsomes.
- Used in research for various cancer types including colon cancer and lymphoma.